Search Results - "Kruit, H."

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy by ULLOA-MONTOYA, Fernando, LOUAHED, Jamila, BRICHARD, Vincent G, DIZIER, Benjamin, GRUSELLE, Olivier, SPIESSENS, Bart, LEHMANN, Frédéric F, SUCIU, Stefan, KRUIT, Wim H. J, EGGERMONT, Alexander M. M, VANSTEENKISTE, Johan

“…To detect a pretreatment gene expression signature (GS) predictive of response to MAGE-A3 immunotherapeutic in patients with metastatic melanoma and to…”
Get full text

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma by KRUIT, Wim H. J, SUCIU, Stefan, BECKER, Juergen C, SPATZ, Alan, EGGERMONT, Alexander M. M, LOUAHED, Jamila, LEHMANN, Frédéric F, BRICHARD, Vincent G, KEILHOLZ, Ulrich, DRENO, Brigitte, MORTIER, Laurent, ROBERT, Caroline, CHIARION-SILENI, Vanna, MAIO, Michele, TESTORI, Alessandro, DORVAL, Thierry, GROB, Jean-Jacques

“…Active immunization against the tumor-specific MAGE-A3 antigen is followed by a few but impressive and durable clinical responses. This randomized phase II…”
Get full text

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma by EGGERMONT, Alexander M. M, SUCIU, Stefan, SCHADENDORF, Dirk, PATEL, Poulam M, DE SCHAETZEN, Gaetan, SPATZ, Alan, KEILHOLZ, Ulrich, TESTORI, Alessandro, SANTINAMI, Mario, KRUIT, Wim H. J, MARSDEN, Jeremy, PUNT, Cornelis J. A, SALES, François, DUMMER, Reinhard, ROBERT, Caroline

“…Adjuvant pegylated interferon alfa-2b (PEG-IFN-α-2b) was approved for treatment of resected stage III melanoma in 2011. Here, we present long-term follow-up…”
Get full text

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial by Eggermont, Alexander MM, Prof, Suciu, Stefan, PhD, Santinami, Mario, MD, Testori, Alessandro, MD, Kruit, Wim HJ, MD, Marsden, Jeremy, MD, Punt, Cornelis JA, Prof, Salès, François, MD, Gore, Martin, Prof, MacKie, Rona, Prof, Kusic, Zvonko, Prof, Dummer, Reinhard, Prof, Hauschild, Axel, Prof, Musat, Elena, MD, Spatz, Alain, MD, Keilholz, Ulrich, Prof

“…Summary Background Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether…”
Get full text

Induction of labor by Foley catheter compared with spontaneous onset of labor after previous cesarean section: a cohort study by Kruit, H, Wilkman, H, Tekay, A, Rahkonen, L

“…Objective: To evaluate the safety of induction of labor (IOL) with Foley catheter (FC) in women with a history of previous cesarean section (CS) and to assess…”
Get full text

Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial by EGGERMONT, Alexander M. M, SUCIU, Stefan, BASTHOLT, Lars, BORGOGNONI, Lorenzo, GRAZIA BERNENGO, Maria, DAVIDSON, Neville, POLDERS, Larissa, PRAET, Michel, SPATZ, Alan, RUTKOWSKI, Piotr, MARSDEN, Jeremy, SANTINAMI, Mario, CORRIE, Philippa, AAMDAL, Steinar, ASCIERTO, Paolo A, PATEL, Poulam M, KRUIT, Wim H

“…The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG antibody…”
Get full text

Foley catheter vs oral misoprostol for induction of labor: individual participant data meta‐analysis by Kemper, J. I., Li, W., Goni, S., Flanagan, M., Weeks, A., Alfirevic, Z., Bracken, H., Mundle, S., Goonewardene, M., Eikelder, M., Bloemenkamp, K., Rengerink, K. O., Kruit, H., Mol, B. W., Palmer, K. R.

“…ABSTRACT Objective To compare the effectiveness and safety of Foley catheter and oral misoprostol for induction of labor (IOL). Methods The Cochrane Review on…”
Get full text

Foley catheter induction of labor as an outpatient procedure by Kruit, H, Heikinheimo, O, Ulander, V-M, Aitokallio-Tallberg, A, Nupponen, I, Paavonen, J, Rahkonen, L

“…Objective: The aim of our study was to introduce outpatient induction of labor by Foley catheter, and to compare outcomes and preferences between in-patients…”
Get full text

Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies—EORTC 18991 by BOUWHUIS, Marna G, SUCIU, Stefan, EGGERMONT, Alexander M. M, TESTORI, Alessandro, KRUIT, Wim H, SALES, François, PATEL, Poulam, PUNT, Cornelis J, SANTINAMI, Mario, SPATZ, Alain, TEN HAGEN, Timo L. M

“…Conflicting data have been reported concerning the prognostic value of autoimmune antibodies in patients with melanoma treated with adjuvant interferon alfa-2b…”
Get full text

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study) by Fusi, Alberto, Collette, Sandra, Busse, Antonia, Suciu, Stefan, Rietz, Anika, Santinami, Mario, Kruit, Wim H.J, Testori, Alessandro, Punt, Cornelis J.A, Dalgleish, Angus G, Spatz, Alan, Eggermont, Alexander M.M, Keilholz, Ulrich

“…Abstract Aim To evaluate the prognostic and predictive importance of detection of melanoma cells in peripheral blood using reverse transcriptase polymerase…”
Get full text

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study) by Busse, Antonia, Rapion, Jérôme, Fusi, Alberto, Suciu, Stefan, Nonnenmacher, Anika, Santinami, Mario, Kruit, Wim H. J., Testori, Alessandro, Punt, Cornelis J. A., Dalgleish, Angus G., Spatz, Alan, Eggermont, Alexander M. M., Keilholz, Ulrich

“…We analysed mRNA levels of interferon response genes (ISG15, STAT1, CXCL10) of inhibitors of the JAK/STAT pathway (STAT3, SOCS1, SOCS3) and of cytokines (TNFα,…”
Get full text

IL-12: a promising adjuvant for cancer vaccination by PORTIELJE, Johanna E. A, GRATAMA, Jan Willem, VAN OJIK, Heidi H, STOTER, Gerrit, KRUIT, Wim H. J

“…The clinical development of interleukin 12 (IL-12) as a single agent for systemic cancer therapy has been hindered by its significant toxicity and…”
Get full text

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma by Kruit, Wim H.J., van Ojik, Heidi H., Brichard, Vincent G., Escudier, Bernard, Dorval, Thierry, Dréno, Brigitte, Patel, Poulam, van Baren, Nicolas, Avril, Marie‐Françoise, Piperno, Sophie, Khammari, Amir, Stas, Marguerite, Ritter, Gerd, Lethé, Bernard, Godelaine, Danièle, Brasseur, Francis, Zhang, Yi, van der Bruggen, Pierre, Boon, Thierry, Eggermont, Alexander M.M., Marchand, Marie

“…The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a…”
Get full text

Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon by Bouwhuis, Marna G., Suciu, Stefan, Collette, Sandra, Aamdal, Steinar, Kruit, Wim H., Bastholt, Lars, Stierner, Ulrika, Salès, François, Patel, Poulam, Punt, Cornelis J. A., Hernberg, Micaela, Spatz, Alain, ten Hagen, Timo L. M., Hansson, Johan, Eggermont, Alexander M. M.

“…Background Appearance of autoantibodies and clinical manifestations of autoimmunity in melanoma patients treated with adjuvant interferon (IFN)-α2b was…”
Get full text

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial by Dreno, Brigitte, Thompson, John F, Smithers, Bernard Mark, Santinami, Mario, Jouary, Thomas, Gutzmer, Ralf, Levchenko, Evgeny, Rutkowski, Piotr, Grob, Jean-Jacques, Korovin, Sergii, Drucis, Kamil, Grange, Florent, Machet, Laurent, Hersey, Peter, Krajsova, Ivana, Testori, Alessandro, Conry, Robert, Guillot, Bernard, Kruit, Wim H J, Demidov, Lev, Thompson, John A, Bondarenko, Igor, Jaroszek, Jaroslaw, Puig, Susana, Cinat, Gabriela, Hauschild, Axel, Goeman, Jelle J, van Houwelingen, Hans C, Ulloa-Montoya, Fernando, Callegaro, Andrea, Dizier, Benjamin, Spiessens, Bart, Debois, Muriel, Brichard, Vincent G, Louahed, Jamila, Therasse, Patrick, Debruyne, Channa, Kirkwood, John M

“…Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic…”
Get full text

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses by PORTIELJE, Johanna E. A, LAMERS, Cor H. J, KRUIT, Wim H. J, SPARREBOOM, Alex, BOLHUIS, Reinder L. H, STOTER, Gerrit, HUBER, Christoph, GRATAMA, Jan W

“…Purpose: Repeated administrations of recombinant human interleukin-12 (rHuIL-12) to cancer patients are characterized by a reduction of side effects during…”
Get full text

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity by Eggermont, Alexander M.M, Suciu, Stefan, Rutkowski, Piotr, Kruit, Willem H, Punt, Cornelis J, Dummer, Reinhard, Salès, François, Keilholz, Ulrich, de Schaetzen, Gaetan, Testori, Alessandro

“…Abstract Background We report on the long term outcome of the EORTC 18952 adjuvant interferon (IFN) trial in 1388 resected stage IIB/III melanoma patients and…”
Get full text

Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991 by Eggermont, Alexander M.M, Suciu, Stefan, Testori, Alessandro, Kruit, Wim H, Marsden, Jeremy, Punt, Cornelis J, Santinami, Mario, Salès, François, Schadendorf, Dirk, Patel, Poulam, Dummer, Reinhard, Robert, Caroline, Keilholz, Ulrich, Yver, Antoine, Spatz, Alan

“…Abstract Summary Adjuvant interferon has modest activity in melanoma patients at high risk for relapse. Patient selection is important; stage and ulceration of…”
Get full text

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors by Kloth, J S L, Pagani, A, Verboom, M C, Malovini, A, Napolitano, C, Kruit, W H J, Sleijfer, S, Steeghs, N, Zambelli, A, Mathijssen, R H J

“…Background: Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc interval on the electrocardiogram (ECG). The QTc-interval…”
Get full text

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer by VAN DER BURG, M. E. L, DE WIT, R, VAN PUTTEN, W. L. J, LOGMANS, A, KRUIT, W. H. J, STOTER, G, VERWEIJ, J

“…We investigated the potential of weekly cisplatin and daily oral etoposide followed by oral etoposide maintenance therapy in patients with platinum-refractory…”
Get full text